Why Knox Lane is taking Cross Country Healthcare private in a $437m all-cash deal
Healthcare staffing is still under pressure. Knox Lane’s $437m Cross Country Healthcare deal turns that reset into a private equity wager.
Pharma & Biotech
Medical Devices & Diagnostics
Can PathoCare’s $1.75bn tender offer reprice the future of AI-driven diagnostics?
Find out why PathoCare's $1.75B valuation and expanded $50M financing round could signal a breakthrough moment for AI-powered point-of-care diagnostics.